業績一覧
2022年 業績
Takeno M. The association of Behcet’s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol .2022; 34:4-9.
Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, Umazume A, Kezuka T, Sakai JI, Goto H. Anti-TNF-α therapy for refractory uveitis associated with Behçet's syndrome and Sarcoidosis: A single center study of 131 patients. Ocul Immunol Inflamm. 2022; 30:223-230.
Tsutsui H, Kikuchi H, Oguchi H, Kono H, Ohkubo T. Validity and reliability of a checklist for patients with Behçet's disease based on the International Classification of Functioning, Disability and Health. Rheumatol Int 2022; 42:159-165.
Takeno M, Dobashi H, Tanaka Y, Kono H, Sugii S, Kishimoto M, Cheng S, McCue S, Paris M, Chen M, Ishigatsubo Y. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study. Mod Rheumatol . 2022; 32:413-421.
Nagano A, Takeuchi M, Horita N, Teshigawara T, Kawagoe T, Mizuki Y, Meguro A, Nakano H, Kirino Y, Takase-Minegishi K, Yoshimi R, Kurosawa M, Fukumoto T, Takeno M, Kaneko T, Mizuki N. Behçet's disease and activities of daily living. Rheumatology. 2022; 61(3):1133-1140.
Hirohata S. Histopathological characteristics of central nervous system in chronic progressive neuro-Behçet's disease. J Neurol Sci. 2022; 434:120127.
Hirahara L, Takase-Minegishi K, Kirino Y, Iizuka-Iribe Y, Soejima Y, Yoshimi R, Nakajima H.The Roles of Monocytes and Macrophages in Behçet’s Disease With Focus on M1 and M2 Polarization. Front Immunol. 2022; 13: 852297.
Su G, Zhong Z, Zhou Q, Du L, Ye Z, Li F, Zhuang W, Wang C, Liang L, Ji Y, Cao Q, Wang Q, Chang R, Tan H, Yi S, Li Y, Feng X, Liao W, Zhang W, Shu J, Tan S, Xu J, Pan S, Li H, Shi J, Chen Z, Zhu Y, Ye X, Tan X, Zhang J, Liu Z, Huang F, Yuan G, Pang T, Liu Y, Ding J, Gao Y, Zhang M, Chi W, Liu X, Wang Y, Chen L, Meguro A, Takeuchi M, Mizuki N, Ohno S, Zuo X, Kijlstra A, Yang P. Identification of Novel Risk Loci for Behçet's Disease-Related Uveitis in a Chinese Population in a Genome-Wide Association Study. Arthritis Rheumatol. 2022; 74:671-681.
Iwata D, Namba K, Yamamoto T, Mizuuchi K, Saito W, Ohno S, Kitaichi N, Ishida S. Recent clinical features of intraocular inflammation in Hokkaido, Japan - comparison with the previous decade. Ocul Immunol Inflamm. 2022; 30: 848-854.
Matsumoto H, Asano T, Tsuchida N, Maeda A, Yoshida S, Yokose K, Fujita Y, Temmoku J, Matsuoka N, Yashiro-Furuya M, Sato S, Irie K, Norikawa N, Yamamoto T, Endo M, Fukuchi K, Ohkawara H, Ikezoe T, Uchiyama Y, Kirino Y, Matsumoto N, Watanabe H, Migita K. Behçet's disease with a somatic UBA1 variant:Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome. Clin Immunol. 2022; 238:108996.
Namba K, Kaburaki T, Tsuruga H, Ogawa Y, Iwashita E, Goto H.: Long-term safety and effectiveness of Adalimumab in Japanese patients with noninfectious intermediate, posterior, or panuveitis: Post-marketing surveillance of 251 patients. Ophthalmol Ther. 2022; 11:1147-1161.
Onaka T, Nakano K, Uemoto Y, Miyakawa N, Otsuka Y, Ogura-Kato A, Iwai F, Tanaka Y, Yonezawa A. Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic / myeloproliferative disease with refractory Behçet’s disease, case report and the review of literature. Mod Rheumatol Case Reports . 2022; 6,273-277.
Umazume A, Ohguro N, Okada AA, Namba K, Sonoda KH, Tsuruga H, Morita K, Goto H.: Use of systemic corticosteroids in patients newly registered at a claims database with a diagnosis of non-infectious uveitis: results from a real-world claims database analysis. Jpn J Ophthalmol. 2022; 66:394-404.
Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. RMD Open. 2022; 8:e002235.
Kawakami T, Yokoyama K, Ikeda T, Nishibata Y, Masuda S, Tomaru U, Ishizu A. The presence of neutrophil extracellular traps in superficial venous thrombosis of Behcet’s disease. J Dermatol. 2022; 49:741-745.
Wakiya R, Ushio Y, Ueeda K, Kameda T, Shimada H, Nakashima S, Kato M, Miyagi T, Sugihara K, Mizusaki M, Mino R, Kadowaki N, Dobashi H. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease. Dermatol Ther. 2022; 35:e15616.
Tsukui D, Hirohata S, Kikuchi H, Uozaki H, Kono H. Histopathology of pulmonary thromboembolism in a patient with Behçet's disease. Clin Exp Rheumatol.2022; 40:1584-1587
Iizuka Y, Takase-Minegishi K, Hirahara L, Kirino Y, Soejima Y, Namkoong HO, Horita N, Yoshimi R, Takeuchi M, Takeno M, Mizuki N, Nakajima H. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis. Mod Rheumatol. 2022; 32:1153-1162.
Tono T, Kikuchi H, Sawada T, Takeno M, Nagafuchi H, Kirino Y, Tanaka Y, Yamaoka K, Hirohata S. Clinical Features of Behçet's Disease Patients with Joint Symptoms in Japan: A National Multicenter Study. Mod Rheumatol . 2022; 32:1146-1152.
Jo YG, Ortiz-Fernández L, Coit P, Yilmaz V, Yentür SP, Alibaz-Oner F, Aksu K, Erken E, Düzgün N, Keser G, Cefle A, Yazici A, Ergen A, Alpsoy E, Salvarani C, Kısacık B, Kötter I, Henes J, Çınar M, Schaefer A, Nohutcu RM, Takeuchi F, Harihara S, Kaburaki T, Messedi M, Song YW, Kaşifoğlu T, Martin J, González Escribano MF, Saruhan-Direskeneli G, Direskeneli H, Sawalha AH. Sex-specific analysis in Behçet's disease reveals higher genetic risk in male patients. J Autoimmun. 2022; 132:102882.
Kim D, Nakamura K, Kaneko F, Alpsoy E, Bang D. Mucocutaneous manifestations of Behcet’s disease : pathogenesis and management from perspectives of vasculitis. Front Med (Lausanne).2022; 9:987393.
Mahmoudi M, Aslani S, Meguro A, Akhtari M, Fatahi Y, Mizuki N, Shahram F. A comprehensive overview on the genetics of Behçet's disease. Int Rev Immunol. 2022; 41:84-106.
Nakamura J, Takeuchi M, Ota M, Mizuki N, Ohno S. Does the Interaction of KIR and HLA Affect the Development of Non-Infectious Uveitis? Curr Mol Med. 2022; 22:703-716.
